🔗 Share this article

Ex-government leader Sunak has intensified his call for a focused screening programme for prostate gland cancer.

In a recently conducted interview, he expressed being "convinced of the immediate need" of introducing such a system that would be economical, achievable and "protect countless lives".

These remarks come as the National Screening Advisory Body reviews its decision from half a decade past not to recommend routine screening.

Media reports propose the body may continue with its current stance.

Athlete Adds Voice to Campaign

Gold medal cyclist Sir Chris Hoy, who has late-stage prostate cancer, advocates for younger men to be screened.

He suggests decreasing the minimum age for obtaining a PSA laboratory test.

At present, it is not standard practice to asymptomatic males who are younger than fifty.

The prostate-specific antigen screening remains debated though. Levels can elevate for causes besides cancer, such as inflammation, leading to misleading readings.

Opponents argue this can lead to unwarranted procedures and side effects.

Focused Screening Initiative

The suggested examination system would concentrate on males between 45 and 69 with a family history of prostate cancer and black men, who experience increased susceptibility.

This population encompasses around over a million individuals in the UK.

Research projections suggest the system would necessitate £25m per year - or about £18 per patient - similar to intestinal and breast testing.

The projection envisions twenty percent of qualified individuals would be contacted yearly, with a seventy-two percent uptake rate.

Diagnostic activity (imaging and tissue samples) would need to rise by twenty-three percent, with only a reasonable growth in NHS staffing, according to the study.

Medical Professionals Reaction

Various healthcare professionals are sceptical about the benefit of screening.

They contend there is still a risk that men will be medically managed for the cancer when it is potentially overtreated and will then have to experience side effects such as urinary problems and impotence.

One respected urology professional commented that "The challenge is we can often detect disease that might not necessitate to be treated and we risk inflicting harm...and my concern at the moment is that risk to reward equation requires refinement."

Patient Perspectives

Individual experiences are also shaping the discussion.

A particular instance concerns a sixty-six year old who, after requesting a PSA test, was diagnosed with the disease at the time of fifty-nine and was informed it had progressed to his pelvis.

He has since experienced chemo treatment, radiotherapy and endocrine treatment but remains incurable.

The man supports screening for those who are potentially vulnerable.

"This is very important to me because of my boys – they are 38 and 40 – I want them screened as quickly. If I had been tested at fifty I am confident I might not be in the circumstances I am currently," he commented.

Next Steps

The Medical Screening Authority will have to assess the data and arguments.

Although the recent study suggests the consequences for staffing and accessibility of a screening programme would be feasible, opposing voices have argued that it would divert diagnostic capabilities away from patients being managed for different health issues.

The continuing dialogue emphasizes the complicated balance between timely diagnosis and likely unnecessary management in prostate gland cancer management.